⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 4, 2026Journal of Antimicrobial ChemotherapyOpen Access

The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions

Sanne van den Berg Marie Attwood Pippa Griffin Alan Noel Shampa Das Markus Zeitlinger Emilie Racine Xavier Boulenc Anouk E Muller Sebastiaan D. T. Sassen Soma Bahmany Marian T. ten Kate Alasdair MacGowan Joseph Meletiadis

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to estimate effective doses of NOSO-502 in humans while analyzing its impact on pathogen clearance and resistance emergence.
Utilized pharmacodynamic index (PDI) targets.
Estimated human pharmacokinetics of NOSO-502.
Analyzed dose-effect relationships.
Effectively estimated doses of NOSO-502 for human use.
Showed potential for significant pathogen clearance.
Identified implications for resistance emergence.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Demonstrates effective dose predictions of NOSO-502 in humans, indicating its potential for pathogen clearance and resistance management.

Abstract

A combination of the use of PDI targets and prediction of human pharmacokinetics allowed effective doses of NOSO-502 in man to be estimated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Berg et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd25fdc3bde448919064 https://doi.org/10.1093/jac/dkag106

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1MexXY-OprM efflux pump mediates resistance to odilorhabdins in <i>Pseudomonas aeruginosa</i>Original Research · 2026
2Human Pharmacokinetic and CYP3A Drug–Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment2024 · 2 citations
3Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and ratsOriginal Research · 2016 · 18 citations
4Exploration of various administration routes for the nitric oxide donating organic nitrite, nitrosooxypropanol, in a porcine modelOriginal Research · 2026
5Physiologically based pharmacokinetic modelling of oxycodone drug–drug interactionsOriginal Research · 2020 · 11 citations
6Exploration of various administration routes for the nitric oxide donating organic nitrite, nitrosooxypropanol, in a porcine modelOriginal Research · 2026
7How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic reviewReview · 2026 · 29 citations
8Antidiarrheal Potential of Psoralidin Through Modulation of <scp>COX</scp> , μ‐Opioid, and L‐Type Calcium Channel Signaling Pathways: In Vivo and In Silico InvestigationsOriginal Research · 2026
9No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studiesJournal of Antimicrobial Chemotherapy · 2026
10Phylogenetic diversification of the PoxtA ribosomal protection determinantJournal of Antimicrobial Chemotherapy · 2026

More from Journal of Antimicrobial Chemotherapy

More from University of Liverpool

More from Erasmus MC

More from Medical University of Vienna

More from National and Kapodistrian University of Athens

More from Southmead Hospital

More from GGD Haaglanden

More from Cyclopharma (France)

More from Evotec (United States)